Literature DB >> 3598226

Human nasal mucosal responses to topically applied recombinant leukocyte A interferon.

F G Hayden, B Winther, G R Donowitz, S E Mills, D J Innes.   

Abstract

Healthy adults were randomly assigned to receive intranasal sprays of recombinant leukocyte A interferon (IFN; 9 X 10(6) U per day) or placebo once daily for four or 10 days. Scrape nasal biopsy specimens stained by hematoxylin and eosin and mucosal punch biopsy specimens stained by immunoperoxidase techniques with monoclonal antibodies to lymphocyte subsets were collected before and after exposure. Blinded analysis of the punch biopsy specimens by two pathologists found increased degrees of lymphocyte infiltration compared with preexposure samples in 56% of IFN vs. 0% of placebo recipients at four days (P = .008) and 60% of IFN vs. 10% of placebo recipients at 10 days (P = .057). By immunoperoxidase staining the cellular infiltrates were primarily in the subepithelium and comprised principally (mean, greater than or equal to 84%) T lymphocytes. In the 10-day IFN recipients, subepithelial T helper (Leu-3):T suppressor (Leu-2) cell ratios ranged from 2:1 to 5:1. The number of distribution of B (Leu-14) or natural killer (Leu-7) cells did not appear affected by IFN.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3598226     DOI: 10.1093/infdis/156.1.64

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds.

Authors:  F G Hayden; D L Kaiser; J K Albrecht
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

Review 2.  Chemotherapy of rhinovirus colds.

Authors:  S J Sperber; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 3.  Respiratory viruses other than influenza virus: impact and therapeutic advances.

Authors:  W Garrett Nichols; Angela J Peck Campbell; Michael Boeckh
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 4.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

Review 5.  Antiviral chemotherapy and prophylaxis of viral respiratory disease.

Authors:  S J Sperber; F G Hayden
Journal:  Clin Lab Med       Date:  1987-12       Impact factor: 1.935

Review 6.  The use of interferon-alpha in virus infections.

Authors:  N B Finter; S Chapman; P Dowd; J M Johnston; V Manna; N Sarantis; N Sheron; G Scott; S Phua; P B Tatum
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.